To include your compound in the COVID-19 Resource Center, submit it here.

Zevalin ibritumomab tiuxetan: Phase II data

A Phase II trial in 60 patients with relapsed/refractory or newly diagnosed high-risk CD20+ NHL who were ineligible for standard ASCT showed that conditioning with

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE